冠状动脉疾病的遗传基础
综述指出冠状动脉疾病的遗传研究推动了机制、治疗、预防和风险预测的进展,现有药物多靶向遗传机制驱动的动脉粥样硬化通路。单基因病因约见于1/250人群,多基因风险评分最高5%者的风险是平均评分者的3至5倍,但其临床价值与实施策略仍待明确。
要点
- 单基因病因约见于1/250人群,多致血脂显著升高。
- 多基因风险评分最高5%者风险为平均者的3至5倍。
- 多基因风险评分的临床价值与成本效果尚待明确。
核心结论
- 冠状动脉疾病的遗传研究已推动机制认识、治疗、预防和风险预测的进步。
- 多基因风险评分可评估个体相对于一般人群的遗传风险,但临床整合策略仍待确定。
研究设计与样本
- 综述性文章,总结冠状动脉疾病遗传基础的研究进展与临床转化问题。
主要发现
- 单基因病因约见于1/250人群,多导致血脂水平大幅升高。
- 数百个效应量小的常见变异在人群层面影响更大,可组合为多基因风险评分。
- 多基因风险评分最高5%者的风险是平均评分者的3至5倍。
- 多基因风险评分的相对风险可乘以临床风险评分得出的绝对风险。
关键数值与推荐
- 单基因病因约1/250人群。
- 多基因风险评分最高5%者风险为平均评分者的3至5倍。
临床怎么用
- 可利用多基因风险评分的相对风险乘以临床风险评分的绝对风险进行风险评估。
- 将多基因风险评分整合入临床实践前需明确其临床价值、成本效果和实施策略。
局限性
- 多基因风险评分的临床价值、成本效果和实施策略尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Investigations of the genetic basis of coronary artery disease have led to advances in mechanistic insights, therapeutics, prevention, and risk prediction. Indeed, most contemporary medicines for coronary artery disease target pathways that promote atherosclerosis due to underpinning genetic mechanisms. Monogenic causes of coronary artery disease occur in approximately 1 out of 250 people and mostly result in massively elevated lipid levels. At the population level, hundreds of common variants with small effect sizes have even greater influence. They can be combined in polygenic risk scores that depict genetic risk in a person relative to the average in the general population. The risk among persons in the highest 5% is 3 to 5 times that among persons with an average score; relative risk derived from the polygenic risk score can be used to multiply the absolute risk derived from a clinical risk score. Key questions remain regarding the clinical value, cost-effectiveness, and implementation strategies required to integrate coronary artery disease polygenic risk scores into clinical practice.
引用
- Schunkert H, Natarajan P, Samani NJ, et al. The Inherited Basis of Coronary Artery Disease. N Engl J Med. 2026. PMID: 41870454. doi:10.1056/NEJMra2405153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。